Past, present and future in low-risk myelodysplastic syndrome

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem cell disorders.
• Characterized by ineffective hematopoiesis, peripheral cytopenias, and a significant risk of transformation to acute myeloid leukemia (AML).
• Prognostic scoring systems like IPSS, revised-IPSS, and WPSS are crucial for risk stratification and treatment decisions.

Purpose of the Study:

• To outline the current understanding of Myelodysplastic syndromes (MDS).
• To emphasize the importance of risk stratification in guiding treatment strategies for MDS.
• To highlight the future direction towards personalized and targeted therapy for MDS.

Main Methods:

• Review of established prognostic scoring systems for MDS (IPSS, revised-IPSS, WPSS).
• Discussion of treatment goals for low-risk MDS.
• Exploration of emerging personalized and targeted approaches.

Main Results:

• Risk stratification using scoring systems is fundamental for MDS management.
• Treatment aims to alleviate cytopenia, reduce transfusion dependence, enhance quality of life, and prolong survival.
• Current strategies focus on improving outcomes and potentially preventing leukemia progression.

Conclusions:

• Accurate prognostication is essential for effective MDS management.
• Personalized treatment strategies incorporating genomics and molecular profiling are anticipated.
• Future approaches promise tailored therapies for improved patient outcomes in MDS.